Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study

Further Publications NeurologyFurther Publications Psychiatry

Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial

Lancet Neurol.

Levin J, Maaß S, Schuberth M, Giese A, Oertel WH, Poewe W, Trenkwalder C, Wenning GK, Mansmann U, Südmeyer M, Eggert K, Mollenhauer B, Lipp A, Löhle M, Classen J, Münchau A, Kassubek J, Gandor F, Berg D, Egert-Schwender S, Eberhardt C, Paul F, Bötzel K, Ertl-Wagner B, Huppertz HJ, Ricard I, Höglinger GU, PROMESA Study Group.

doi: 10.1016/S1474-4422(19)30141-3.

Aging and Cognitive Functions

Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis

J Neurol Neurosurg Psychiatry.

Glasmacher SA, Leigh PN, Saha RA

doi: 10.1136/jnnp-2016-314956.

Multiple Sclerosis

Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.

J Neurol.

Kamm CP, Barin L, Gobbi C, Pot C, Calabrese P, Salmen A, Achtnichts L, Kesselring J, Puhan MA, von Wyl V, Swiss Multiple Sclerosis Registry (SMSR).

doi: 10.1007/s00415-019-09563-y.

Multiple Sclerosis

Improved Assessment of Longitudinal Spinal Cord Atrophy in Multiple Sclerosis Using a Registration-Based Approach: Relevance for Clinical Studies

J Magn Reson Imaging

Valsasina P, Horsfield MA, Meani A, Gobbi C, Gallo A, Rocca MA, Filippi M

doi: 10.1002/jmri.27937

Multiple Sclerosis

No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

J Neurol.

Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group

doi: 10.1007/s00415-018-9070-x.

Aging and Cognitive FunctionsMultiple Sclerosis

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

J Neurol.

Comi G, Patti F, Rocca MA, Mattioli FC, Amato MP, Gallo P, Centonze D, Pozzilli C, Saccà F, Bergh FT, Bartezaghi M, Turrini R, Filippi M; Golden Study Group

doi: 10.1007/s00415-017-8642-5.

RECOMMENDED

Parkinson’s Disease

Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives

Acta Neuropathol Commun.

Monzio Compagnoni G, Di Fonzo A

doi: 10.1186/s40478-

Multiple Sclerosis

Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies

Ann Neurol.

Maggi P, Absinta M, Grammatico M, Vuolo L, Emmi G, Carlucci G, Spagni G, Barilaro A, Repice AM, Emmi L, Prisco D, Martinelli V, Scotti R, Sadeghi N, Perrotta G, Sati P, Dachy B, Reich DS, Filippi M, Massacesi L

doi: 10.1002/ana.25146.

Multiple Sclerosis

The "central vein sign" in patients with diagnostic "red flags" for multiple sclerosis: A prospective multicenter 3T study

Mult Scler.

Maggi P, Absinta M, Sati P, Perrotta G, Massacesi L, Dachy B, Pot C, Meuli R, Reich DS, Filippi M, Pasquier RD, Théaudin M

doi: 10.1177/1352458519876031.

Related content

Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial

Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis

Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.

Improved Assessment of Longitudinal Spinal Cord Atrophy in Multiple Sclerosis Using a Registration-Based Approach: Relevance for Clinical Studies

No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives

Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies

The "central vein sign" in patients with diagnostic "red flags" for multiple sclerosis: A prospective multicenter 3T study